NPPB and diabetes mellitus: Results from this trial indicate canagliflozin administered for 24 weeks to elderly patients with diabetes and stable chronic HF was not noninferior regarding percentage change in N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, possibly due to the large variation in NT-proBNP levels.